12 Health Care Stocks Moving In Tuesday's After-Market Session

Benzinga · 5d ago
Gainers
- Catheter Precision (AMEX:VTAK) stock increased by 97.3% to $0.45 during Tuesday's after-market session. The company's market cap stands at $4.9 million.
- Serina Therapeutics (AMEX:SER) stock moved upwards by 23.08% to $7.25. The company's market cap stands at $72.2 million.
- Nuwellis (NASDAQ:NUWE) stock rose 11.08% to $0.26. The company's market cap stands at $1.1 million.
- Windtree Therapeutics (NASDAQ:WINT) stock increased by 10.12% to $0.87. The company's market cap stands at $3.1 million.
- Imunon (NASDAQ:IMNN) stock moved upwards by 7.97% to $1.75. The market value of their outstanding shares is at $30.6 million.
- SunLink Health Systems (AMEX:SSY) shares moved upwards by 7.07% to $1.06. The market value of their outstanding shares is at $7.4 million.
Losers
- NuCana (NASDAQ:NCNA) shares fell 18.4% to $0.12 during Tuesday's after-market session.
- Gelteq (NASDAQ:GELS) shares decreased by 14.92% to $2.51. The market value of their outstanding shares is at $23.6 million.
- CARISMA Therapeutics (NASDAQ:CARM) shares declined by 14.08% to $0.93. The market value of their outstanding shares is at $38.7 million.
- Abpro Hldgs (NASDAQ:ABP) stock decreased by 9.88% to $0.25. The market value of their outstanding shares is at $15.1 million.
- Citius Oncology (NASDAQ:CTOR) stock decreased by 6.26% to $1.2. The company's market cap stands at $85.8 million.
- Inogen (NASDAQ:INGN) shares declined by 5.52% to $6.25. The company's market cap stands at $168.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.